AR 101

Drug Profile

AR 101

Alternative Names: Characterised Peanut Allergen (CPNA) oral immunotherapy (OIT) - Aimmune Therapeutics; Peanut allergy immunotherapy - Aimmune Therapeutics; Peanut allergy OIT - Aimmune Therapeutics

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergen Research Corporation
  • Developer Aimmune Therapeutics; Guys and St. Thomas Hospital NHS Trust
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peanut hypersensitivity

Most Recent Events

  • 16 Jun 2017 Aimmune Therapeutics initiates enrolment in the ARTEMIS trial for Peanut hypersensitivity (In children, in adolescents) in Spain and Ireland (EudraCT2016-005004-26)
  • 12 Jun 2017 Phase-III clinical trials in Peanut hypersensitivity (In children, In adolescents) in United Kingdom (PO) (NCT03201003)
  • 01 May 2017 Aimmune Therapeutics initiates enrolment in the phase III RAMSES trial for Peanut hypersensitivity (In adolescents, In children) in USA (PO) (NCT03126227)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top